Literature DB >> 20176685

Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury.

Irene Paterniti1, Emanuela Esposito, Emanuela Mazzon, Maria Galuppo, Rosanna Di Paola, Placido Bramanti, Amar Kapoor, Christoph Thiemermann, Salvatore Cuzzocrea.   

Abstract

Several lines of evidence suggest a biological role for peroxisome proliferator-activated receptor (PPAR)-beta/delta in the pathogenesis many diseases. The aim of the present study was to evaluate the contribution of PPAR-beta/delta in the secondary damage in experimental spinal cord injury (SCI) in mice. To this purpose, we used 4-[[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenoxy]acetic acid (GW0742), a high-affinity PPAR-beta/delta agonist. Spinal cord trauma was induced by the application of vascular clips (force of 24 g) to the dura via a four-level T5 to T8 laminectomy. SCI in mice resulted in severe trauma characterized by edema, neutrophil infiltration, production of inflammatory mediators, tissue damage, and apoptosis. GW0742 treatment (0.3 mg kg(-1) i.p.) 1 and 6 h after the SCI significantly reduced 1) the degree of spinal cord inflammation and tissue injury (histological score), 2) neutrophil infiltration (myeloperoxidase activity), 3) nitrotyrosine formation, 4) proinflammatory cytokines expression, 5) nuclear factor-kappaB activation, 6) inducible nitric-oxide synthase expression, and 6) apoptosis (terminal deoxynucleotidyl transferase dUTP nick-end labeling staining, FasL, Bax, and Bcl-2 expression). Moreover, GW0742 significantly ameliorated the recovery of limb function (evaluated by motor recovery score). To elucidate whether the protective effects of GW0742 are related to activation of the PPAR-beta/delta receptor, we also investigated the effect of PPAR-beta/delta antagonist methyl 3-({[2-(methoxy)-4 phenyl]amino}sulfonyl)-2-thiophenecarboxylate (GSK0660) on the protective effects of GW0742. GSK0660 (1 mg/kg i.p. 30 min before treatment with GW0742) significantly blocked the effect of the PPAR-beta/delta agonist and thus abolished the protective effect. Our results clearly demonstrate that GW0742 treatment reduces the development of inflammation and tissue injury associated with spinal cord trauma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20176685     DOI: 10.1124/jpet.110.165605

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.402


  26 in total

Review 1.  Organotypic Spinal Cord Culture: a Proper Platform for the Functional Screening.

Authors:  Sareh Pandamooz; Mohammad Nabiuni; Jaleel Miyan; Abolhassan Ahmadiani; Leila Dargahi
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

Review 2.  Therapeutic implications of disorders of cell death signalling: membranes, micro-environment, and eicosanoid and docosanoid metabolism.

Authors:  J Davidson; D Rotondo; M T Rizzo; H A Leaver
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 3.  Activation of PPARδ: from computer modelling to biological effects.

Authors:  Shirin Kahremany; Ariela Livne; Arie Gruzman; Hanoch Senderowitz; Shlomo Sasson
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

Review 4.  Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis.

Authors:  Jeffrey M Peters; Jennifer E Foreman; Frank J Gonzalez
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 5.  Peroxisome proliferator activating receptor (PPAR) in cerebral malaria (CM): a novel target for an additional therapy.

Authors:  S Balachandar; A Katyal
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-12-09       Impact factor: 3.267

Review 6.  Nuclear receptors in neurodegenerative diseases.

Authors:  Rebecca Skerrett; Tarja Malm; Gary Landreth
Journal:  Neurobiol Dis       Date:  2014-05-27       Impact factor: 5.996

7.  The peroxisome proliferator-activated receptor-β/δ antagonist GSK0660 mitigates retinal cell inflammation and leukostasis.

Authors:  Megan E Capozzi; Sara R Savage; Gary W McCollum; Sandra S Hammer; Carla J Ramos; Rong Yang; Colin A Bretz; John S Penn
Journal:  Exp Eye Res       Date:  2019-11-20       Impact factor: 3.467

8.  Anti-inflammatory and anti-hyperalgesic effect of all-trans retinoic acid in carrageenan-induced paw edema in Wistar rats: involvement of peroxisome proliferator-activated receptor-β/δ receptors.

Authors:  Navneet Gill; Krishna Reddy V Bijjem; Pyare L Sharma
Journal:  Indian J Pharmacol       Date:  2013 May-Jun       Impact factor: 2.833

9.  Cardiac peroxisome proliferator-activated receptor δ (PPARδ) as a new target for increased contractility without altering heart rate.

Authors:  Zhih-Cherng Chen; Kung Shing Lee; Li-Jen Chen; Lin-Yu Wang; Ho-Shan Niu; Juei-Tang Cheng
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.752

10.  Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma.

Authors:  Irene Paterniti; Daniela Impellizzeri; Rosalia Crupi; Rossana Morabito; Michela Campolo; Emanuela Esposito; Salvatore Cuzzocrea
Journal:  J Neuroinflammation       Date:  2013-02-01       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.